secwatch.observer — SEC 8-K summary
======================================

Issuer:     TherapeuticsMD, Inc. (TXMD)
CIK:        0000025743
Form:       8-K
Filed at:   2022-04-27T23:59:59+00:00
Accession:  0001564590-22-016083
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

TherapeuticsMD announces 1-for-50 reverse stock split to regain Nasdaq bid price compliance
--------------------------------------------------------------------------------

- Board approves 1-for-50 reverse stock split to cure Nasdaq minimum bid price non-compliance.
- Effective May 6, 2022 at 5:00 p.m. ET; post-split trading on Nasdaq under "TXMD" begins May 9, 2022.
- No stockholder vote required; fractional shares rounded up to nearest whole share.
- Nasdaq granted extension to June 1, 2022 to regain compliance with $1.00 bid price.
- Authorized shares reduced from 600 million to 12 million; authorized reduction matches split.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/25743/000156459022016083/0001564590-22-016083-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/25743/000156459022016083/txmd-8k_20220427.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-016083

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer